Philip Morris Set Out to Kill Its Own Cigarette. It Got Halfway, and the Half That Stalled Tells You Why.

In November 2014, the world's largest tobacco company put a battery-powered metal stick the size of a fountain pen on a few shelves in Nagoya, Japan, and a few more in Milan.¹ It heated tobacco instead of burning it. It was not a nationwide product, not even close — Japan's actual rollout didn't begin until September 2015.¹ But that quiet pilot was a company taking aim at the single most profitable consumer product ever sold: its own cigarette. Philip Morris was loading a gun and pointing it at Marlboro.

The story usually told is heroic and simple: a cigarette giant saw the future, bet billions, and replaced its own poison with something better. Almost every beat of that is true — and the conclusion is still wrong. PMI did bet billions, and it did move further than any competitor dared. But a decade later the gun is still half-loaded, the bullet missed the United States entirely, and the company's own numbers can't agree on whether it actually hit the target.

Here is the thesis a smart friend can repeat: PMI's IQOS pivot is the most credible self-disruption in the history of tobacco — and it is only half-complete, because cannibalizing a near-perfect cash cow turns out to be far harder than building the replacement.

What it actually costs to shoot your own cash cow

Most companies that talk about disrupting themselves never pull the trigger, because the thing they'd be killing is the thing that pays for everything else. A cigarette is the closest thing commerce has to a perpetual motion machine: a chemically addictive, habit-formed product with enormous margins and a customer who returns every single day. To disrupt that on purpose, a company has to be willing to lose money it is currently, reliably making. PMI did the unglamorous version of that — it spent. Since 2008 it has poured over $16 billion into smoke-free product development.⁶ The root runs even deeper than the 2014 launch suggests; the R&D dates back more than a decade and a half before that became a public number.⁶ This was not a marketing pivot. It was a capital reallocation away from the most profitable product the company sells, toward one that had to earn its margins from scratch.

And the spending bought a result that looked, for a moment, like victory. In the fourth quarter of 2023, IQOS surpassed Marlboro in net revenues — the new product outselling the most famous cigarette brand on earth.² CEO Jacek Olczak put it in the earnings release: smoke-free reached nearly 40% of total net revenues and over 40% of gross profit in that quarter.³ By full-year 2025, smoke-free products were 41.5% of total net revenues.⁶ No other tobacco major has moved that share that far. If self-disruption were a sport, PMI would be on the podium alone.

Why 'IQOS beat Marlboro' is the easiest number to misread

Read the headline again and notice what it quietly does. 'IQOS surpassed Marlboro' is a brand-versus-brand comparison — one product line outselling one cigarette brand in one quarter.³ It is not the same as smoke-free surpassing combustibles overall. The full-year picture is far less dramatic: even at 41.5% smoke-free, the majority of PMI's net revenue still comes from setting tobacco on fire.⁶ The cash cow is wounded, not slain. PMI knows the difference, which is why its own September 2023 Investor Day set the real finish line in the future — smoke-free to exceed two-thirds of net revenues by 2030.⁸ You don't set a 2030 target for something you've already accomplished. The 'IQOS beat Marlboro' moment was a milestone dressed as a destination.

The bullet that never reached America

If you want to see the structural ceiling on this strategy, look at the world's most valuable tobacco market, where IQOS effectively cannot be sold. The cause was not the FDA reversing a safety judgment — that's the popular misremembering. On September 29, 2021, the US International Trade Commission ruled that IQOS infringed two patents held by R.J. Reynolds, a subsidiary of rival BAT, and ordered PMI and Altria to halt US imports and sales.⁵ President Biden declined to overturn the order that November.⁵ A patent fight, not a regulator's change of heart — and that distinction matters enormously. A safety ruling can be re-litigated with new science. A competitor's patent is a wall built by the people who most want you to fail. The single largest market for the replacement product got closed by the same dynamic that makes the cigarette business so defensible: incumbents protect their turf with everything they have, and now PMI is the one being kept out.

Did anyone actually quit — or just switch the shape of the habit?

The whole moral case for self-disruption rests on one claim: that the new product moves people off cigarettes. PMI's 2023 Annual Report states that roughly 73% of IQOS users had stopped smoking.² That figure is doing extraordinary load-bearing work in every press release and every public-health argument the company makes. But the Bureau of Investigative Journalism flagged a discrepancy PMI cannot easily wave away: the company's own 2020 FDA filings put the share of Japanese IQOS users who no longer smoke at just 14%.⁷ Both numbers come from PMI. The gap between them is the gap between two very different businesses — one that replaces a deadly habit, and one that upsells a nicotine-dependent customer to a higher-margin delivery device while they keep their cigarettes in the other pocket. 'Stopped smoking combustibles' is not the same as 'quit nicotine,' and no regulator has independently validated the headline figure.⁷ When a company's own disruption metric varies by 59 points depending on which filing you read, the disruption is at least partly a narrative.

The strongest case for the bulls — and why it's still incomplete

The fair objection is that this is grading on perfection. No incumbent has ever fully replaced its own core product inside a decade, and PMI has gone demonstrably further than every rival — 41.5% of revenue from smoke-free, IQOS outselling Marlboro, a clear path to two-thirds by 2030, and a $16 billion war chest backing it.⁶²⁸ It even bought optionality beyond heated tobacco: in May 2022 it offered roughly $16 billion for Swedish Match to add smokeless nicotine pouches to the portfolio.⁴ That is a company treating transformation as a generational project, not a quarter. All true. But 'further than anyone else' is a comparison, not a finish, and the honest counter is that the two hardest questions remain open. Can the strategy survive in a market it's been legally locked out of? And does the product actually do what the moral story claims — move people off cigarettes — when the company's own numbers can't settle on an answer? Until both are resolved, this is a brilliant first half, scored as if the game were over.

Philip Morris pointed a loaded gun at the most profitable product in consumer history and pulled the trigger — which almost no incumbent ever does. That alone makes it the most credible self-disruption tobacco has seen. But the bullet hit a wound, not a heart: the cash cow still bankrolls the transition, a rival's patent froze the whole plan out of America, and the switch-rate data tells two stories at once. The lesson isn't that PMI failed. It's that disrupting yourself is two acts, and everyone applauds the first one. The first act is spending the money and shipping the replacement. The second — proving the old margin is gone and not merely re-packaged — is the one PMI is still, expensively, in the middle of.